Response to: Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment' by Felson *et al*

We read with interest the communication by Ferreira and colleagues on our editorial about the measurement of remission in rheumatoid arthritis.¹ They agree with large parts of our editorial, particularly the importance of including patient-reported outcomes (PROs) in the evaluation of rheumatoid arthritis (RA) disease activity. Their main argument is that a PRO such as the patient global assessment does not capture active RA when the 28-joint counts suggest quiescent disease. For example, in one paper, they suggested that the main predictors of patient global assessment in patients with a small number of swollen and tender joints in the 28-joint count are pain and fatigue.²

The 28-joint count was adopted as an RA outcome measure based on data that suggested this reduced count (ignoring feet/ankles/hips/neck) could adequately capture response to treatment. It was never intended to comprehensively assess all active joints. The pain experienced by patients with persistently elevated patient global assessments who have low 28-joint count levels may well be due to RA disease activity affecting joints not counted, joints that are often affected by RA: in fact, one of Ferreira's coauthors championed the assessment of structural disease in the feet, showing that including this site enhanced our ability to comprehensively assess structural damage in RA. We believe that patient global assessment gives us a window into overall disease activity including disease in these other joints. We further note that one active joint among the 28 joints counted can cause patients considerable suffering and can serve as the basis for elevated patient global assessment scores. In psoriatic arthritis, investigators recently agreed to readopt a 66/68 joint count to evaluate outcomes including remission for the reasons outlined previously.³

Ferreira and colleagues argue that they are 'concerned' about overtreatment that may lead to unnecessary exposure to potentially harmful medicines. They assert that there is a sizeable group of patients in 'near-remission'^{4 5} because they fail to reach the PGA cutpoint of ≤ 1 and that additional treatment of these patients would constitute overtreatment. However, we disagree with the concern about overtreatment: no single study has to date shown that overtreatment is a problem. In a recent publication using 44-Joint Disease Activity Score (DAS44) of <1.6 as the treat-to-target goal, 38% of patients with RA not on target were found to not have treatments increased (ie, were undertreated), while only 9% of those with treatment increased were actually at the DAS44 target of <1.6 . So, while the concern of our colleagues for patients is appreciated, evidence suggests that the main problem is undertreatment and *not* overtreatment in patients with RA. With all the therapies available to patients with RA, all efforts by the scientific community should be taken to achieve remission for at least the majority of our patients in the third decade of the 21st century.

Our colleagues argue in favour of using C-reactive protein (CRP) as the main outcome since it reflects the inflammatory response. However, as noted in our editorial, effective RA treatments have variable effects on CRP with some, such

as anti-interleukin-6 agents and Janus kinase (JAK) inhibitors, causing a drop in CRP, whereas others do not affect CRP. Considering also the possibility that CRP may reflect infection and not inflammation, an exclusion of CRP from composite instruments would therefore follow an analogous logic as PGA exclusion. All this would be a dramatic step back in time, before composite measures had been introduced to cover the activity of a complex systemic disease such as RA.

Lastly, we are concerned that a dual target as proposed by Ferreira *et al*⁴ will make it easier for sponsors of new treatments to focus on the easier to achieve target for approval (as has already occurred with the 28-Joint Disease Activity Score (DAS28) remission thresholds). If so, the 'dual-target approach' would lead to ignoring patient assessments entirely. Although the authors argue that separating PROs from objective markers will serve patient interests, the reality will likely be the opposite, with the separation leading to PROs being 'measured on the side, as a secondary outcome'. So in our view, the only guarantee that PROs will not be 'put aside' is if they continue to remain an integral—and thus required—part of disease activity instruments.

David Felson ¹, Diane Lacaille,^{2,3} Michael P LaValley,⁴ Daniel Aletaha ⁵

¹Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA

²Department of Medicine, Arthritis Research Canada, Richmond, British Columbia, Canada

³Medicine, Division of Rheumatology, University of British Columbia, Richmond, British Columbia, Canada

⁴Biostatistics, School of Public Health, Boston, Massachusetts, USA

⁵Department of Rheumatology, Medical University of Vienna, Vienna, Austria

Correspondence to Professor David Felson, Boston University School of Medicine, Boston, MA 02118, USA; dfelson@bu.edu

Handling editor David S Pisetsky

Funding This study was funded by National Institutes of Health (P30 AR072571).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study does not involve human participants.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Felson D, Lacaille D, LaValley MP, *et al*. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2021-221941

Received 8 December 2021

Accepted 26 January 2022

► <http://dx.doi.org/10.1136/annrheumdis-2021-221941>

Ann Rheum Dis 2022;**0**:1–2. doi:10.1136/annrheumdis-2021-221941

ORCID iDs

David Felson <http://orcid.org/0000-0002-2668-2447>

Daniel Aletaha <http://orcid.org/0000-0003-2108-0030>

REFERENCES

- 1 Ferreira RJO, Welsing PMJ, Jacobs JWG. Correspondence on "Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment" by Felson *et al*. *Ann Rheum Dis*.

- 2 Ferreira RJO, Dougados M, Kirwan JR, *et al*. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. *Rheumatology* 2017;56:1573–8.
- 3 Duarte-García A, Leung YY, Coates LC, *et al*. Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 psoriatic arthritis workshop report. *J Rheumatol* 2019;46:996–1005.
- 4 Ferreira RJO, Duarte C, Ndosi M, *et al*. Suppressing inflammation in rheumatoid arthritis: does patient global assessment blur the target? A practice-based call for a paradigm change. *Arthritis Care Res* 2018;70:369–78.
- 5 Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. *Ann Rheum Dis* 2012;71:1702–5.